Apricus Biosciences, Inc (NASDAQ:APRI)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Tuesday. They presently have a $4.50 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 188.46% from the company’s previous close.

Separately, Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Friday, August 4th.

Shares of Apricus Biosciences (APRI) opened at 1.56 on Tuesday. The firm has a market cap of $19.94 million, a price-to-earnings ratio of 2.60 and a beta of 0.55. The firm has a 50-day moving average of $1.38 and a 200-day moving average of $1.53. Apricus Biosciences has a 12 month low of $0.86 and a 12 month high of $4.94.

Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Wednesday, August 2nd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. On average, analysts anticipate that Apricus Biosciences will post ($0.81) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Apricus Biosciences, Inc (APRI) Stock Rating Reaffirmed by HC Wainwright” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/07/apricus-biosciences-inc-apri-stock-rating-reaffirmed-by-hc-wainwright.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Stock Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related stocks with our FREE daily email newsletter.